Individual-based modeling of potential poliovirus transmission in connected religious communities in north america with low uptake of vaccination

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S424-S433

  Kisjes, Kasper H ^a,b   Tebbens, Radboud J Duintjer ^a   Wallace, Gregory S ^c   Pallansch, Mark A ^c   Cochi, Stephen L ^d   Wassilak, Steven G F ^d   Thompson, Kimberly M ^a,e  

^a Kid Risk Inc   (United States)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

disease outbreaks; heterogeneity; immunization; individual based model; polio

Indexed keywords

AMISH; ARTICLE; COMMUNITY ASSESSMENT; DISEASE TRANSMISSION; FEMALE; HUMAN; IMMUNITY; INDIVIDUAL BASED MODEL; INFECTION CONTROL; MALE; MODEL; NORTH AMERICA; POLIOMYELITIS; RELIGION; VACCINATION; ADOLESCENT; ADULT; AGED; CHILD; DEMOGRAPHY; EPIDEMIOLOGY; INFANT; ISOLATION AND PURIFICATION; MIDDLE AGED; NEWBORN; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; RISK ASSESSMENT; STATISTICAL MODEL; TRANSMISSION; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

POLIOMYELITIS VACCINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMISH; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, STATISTICAL; NORTH AMERICA; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; RESIDENCE CHARACTERISTICS; RISK ASSESSMENT; VACCINATION; YOUNG ADULT;

EID: 84910658010     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit843     Document Type: Article

References (40)

1. Thompson KM, Duintjer Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal 2006; 26:1423-40.
2. Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006; 26:1471-505.
3. WHO. Global Polio Eradication Initiative-list of wild poliovirus by country. http://www.polioeradication.org/dataandmonitoring/poliothisweek/wildpolioviruslist.aspx. Accessed 13 November 2013.
4. WHO. Global Polio E radication Initiative-circulating vaccine-derived poliovirus (cVDPV) 2000-2013. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx. Accessed 13 November 2013.
5. Alexande r JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 2009; 199:391-7.
6. Centers for Disease Control and Prevention. Current trends lack of evidence for wild poliovirus circulation-United States, 1993. MMWR 1995; 43:957-9.
7. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal 2006; 26:1541-56.
8. Eubank S, Guclu H, Kumar VSA, et al. Modelling disease outbreaks in realistic urban social networks. Nature 2004; 429:180-4.
9. Eubank S. Network based models of infectious disease spread. Jpn J Infect Dis 2005; 58:S9-13.
10. Carrat F, Luong J, Lao H, Sallé AV, Lajaunie C, Wackernagel H. A 'small-world-like' model for comparing interventions aimed at preventing a nd controlling influenza pandemics. BMC Med 2006; 4:26.
11. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SGF, Cochi SL, Thompson KM. Characterizing poliovirus transmission an d evolution: Insights from modeling experiences with wild and vaccinerelated polioviruses. Risk Anal 2013; 33:703-49.
12. Thompson KM,Wallace GS, Tebbens RJD, et al. Trends in the risk of U. S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep 2012; 127:23-37.
13. Helbing D, Balietti S. Agent-based modeling. Chapter 2. In: Helbing D, ed. Social self-organization. Berlin: Springer, 2012, 25-70.
14. Longini IM Jr., Nizam A, Xu S, et al. Containing pandemic influenza at the source. Science 2005; 309:1083-7.
15. Germann TC, Kadau K, Longini IM Jr., Macken CA. Mitigation strategies for pandemic influenza in the United States. P Natl Acad Sci U S A 2006; 103:5935-40.
16. Parker J, Ep stein JM. A distributed platform for global-scale agentbased models of disease transmission. ACM T Model Comput S 2011; 22:2.
17. Tsai YS, Huang CY, Wen TH, Sun CT, Yen MY. Integra ting epidemic dynamics with daily commuting networks: Building a multilayer framework to assess influenza A (H1N1) intervention policies. Simulation 2011; 87:385-405.
18. Heppenstall AJ, Crooks AT, See L M, Batty M. eds. Agent-based models of geographical systems. Dordrecht: Springer, 2012.
19. Rahmandad H,Hu K,Tebbens RJD,Thompson KM. Development of an individual-based model for polioviruses: Implicatio ns of the selection of network type and outcome metrics. Epidemiol Infect 2011 139 836-48.
20. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Expert review on poliovirus immunity and transmission. Risk Anal 2013; 33:544-605.
21. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal 2013; 33:606-46.
22. Duintje r Tebbens RJ, Kalkowska DA, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis 2014; 14:45.
23. Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: Perspectives from modeling and prerequisites for OPV cessation. Expert Rev Vaccines 2012; 11: 449-59.
24. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Kim JH, Cochi SL. Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Anal 2013; 33:516-43.
25. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal 2013; 33:647-63.
26. Amish StudiesWeb site. Young Center for Anabaptist and Pietist Studies (YCAPS). http://www2.etown.edu/amishstudies/. Accessed 17 April 2013.
27. Bial R. Visit to Amish Country. Urbana, IL: Phoenix Publishing, 1995.
28. Kraybill DB. The riddle of Amish culture. Baltimore, MD: Johns Hopkins University Press, 2001.
29. Wagner K. Life in an Amish Community. San Diego, CA: Lucent Books, 2001.
30. Stevick RA. Growing up Amish: The teenage years. Baltimore, MD: Johns Hopkins University Press, 2007.
31. Hostetler JA. Amish Society. Baltimore, MD: Johns Hopkins University Press, 1993.
32. Kraybill DB, Johnson-Weiner KM, Nolt SM. The Amish. Baltimore, Maryland: The John Hopkins University Press, 2013.
33. Marine WM, Chin TD, Gravelle CR. Limitati on of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am J Hyg 1962; 76:173-95.
34. Nathanson N, Kew OM. From emergence to eradication: The epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010; 172: 1213-29.
35. Chen RT, Hausinger S, Dajani AS, et al. Seroprevalence of antibody against poliovirus in inner- city preschool children: Implications for vaccination policy in the United States. JAMA 1996; 275:1639-45.
36. Wenger OK, McManus MD, Bower JR, Langkamp DL. Underimmunization in Ohio' s Amish: Parental fears are a greater obstacle than access to care. Pediatrics 2011; 128:79-85.
37. Yoder JS, Dworkin MS. Vaccination usage among an old-order Amish community in Illinois. Pediatr Infect Dis J 2006; 25:1182-3.
38. Wilensky U. NetLogo. http://ccl.northwestern.edu/netlogo/. Accessed 5 August 2012.
39. Alexander L, Birkhead G, Guerra F, et al. Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP). Arch Pediatr Adol Me d 2004; 158:1106-12.
40. Duintjer Tebbens RJ,Pallansch MA,Alexander JP,Thompson KM. Optimal vaccine stockpile design for an eradicated disease: Application to polio. Vaccine 2010 28, 4312-27.